FairJourney Biologics, a leading antibody discovery, engineering and production CRO, today announced that they have patented an innovative technology to discover antibody molecules in full therapeutic format.
Currently, phage display selected antibody fragments are converted to immunoglobulins or to Fc fusion proteins and expressed in mammalian cells. The resulting final molecules are bivalent, possess Fc effector function and a half-life comparable to natural immunoglobulins. The conversion process is time consuming in antibody discovery and for some antibody fragments it may result in loss of activity. The recently developed technology, named “triple vector”, enables the selection of immunological effector function bearing bivalent molecules by phage display as well as the production of such molecules in bacteria and mammalian systems without the need of any cloning step, consequently accelerating drug discovery process and yielding unique sequences.
“FairJourney Biologics, a privately held and sustainable biotech company, is committed to push the boundaries of phage display technology to discover superior antibodies for its partners,” commented António Parada CEO of FairJourney Biologics.
FairJourney Biologics is one of the leading antibody discovery, engineering and production CROs in the world. Working for several big pharma and leading biotech companies, using immune and naïve libraries of different antibody formats, was successful in moving the pipeline of these companies thru its deep understanding of phage display technology. Being a profitable company, it enabled the possibility to maintain long lasting relationships and to explore ground breaking technologies.